CanSinoBIO’s Protein-based Pneumococcal Vaccine Candidate Received Clinical Approval from Chinese Regulatory Agency NMPA
2018-10-31 READ MORE
New UK-China biotech collaboration to develop shingles vaccine
Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of China’s CanSino Biologics in collaboration focused on herpes zoster. Oxford, UK and Tianjin, China – 14th September 2018 – FOR IMMEDIATE RELEASE
2018-09-14 READ MORE
National Research Council contribution plays key role in newly approved Ebola vaccine
March 20, 2018 – Montreal, QC - In response to the Ebola outbreak that claimed more than 10,000 lives in West Africa four years ago, Canada and China worked on a new Ebola vaccine.
2018-03-22 READ MORE
CanSino Submits a Clinical Trial Application for the Component DTP Diptheria Tetanus Pertussis Combo Vaccine (Adults, Teenagers and Children Above 6 Years Old)
August 2 nd 2016, Tianjin CanSino submits the Clinical trial applicationfor the component DTP combo vaccine andsuccessfullyreceives the “drug application registration”. This product is the first DTP vaccine ...
2016-08-03 READ MORE
World TB Day is March 24. Help us bring an end to the epidemic by supporting TB vaccine research.
Ridding the World of Tuberculosis
2016-03-24 READ MORE
Copyright © ( 2017) CanSino Biologics Inc
For the record: 津ICP备14006666号-2